NCT01174173View on ClinicalTrials.gov

Ranolazine and Pulmonary Hypertension

PHASE3CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

October 31, 2014

Conditions

AnginaPulmonary Arterial Hypertension

Interventions

DRUG

Ranolazine

ranolazine 1000 mg PO BID for 3 months

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Northwestern University

OTHER